Ionis Pharmaceuticals INC 8-K filings

Ionis Pharmaceuticals has granted Otsuka Pharmaceutical exclusive rights to commercialize donidalorsen in the Asia-Pacific region, expanding their existing partnership.

Ionis Pharmaceuticals successfully held its annual meeting, electing directors, approving executive compensation, increasing share authorization for its equity plan, and ratifying its auditors.

Ionis Pharmaceuticals reported positive results from Phase 3 trials of donidalorsen, showing significant reductions in hereditary angioedema attacks and improved quality of life for patients.

Ionis Pharmaceuticals announced its first quarter 2024 financial results, highlighting the launch of WAINUA and progress in its pipeline.

Ionis Pharmaceuticals' olezarsen demonstrated significant reductions in triglycerides and acute pancreatitis events in a Phase 3 trial for familial chylomicronemia syndrome (FCS).

Ionis Pharmaceuticals has announced the appointment of Kyle Jenn as executive vice president of commercial and the departure of Onaiza Cadoret-Manier, who will transition to an advisory role.

Ionis Pharmaceuticals announced positive financial results for 2023, driven by pipeline advancements and technology platform success, and provided financial guidance for 2024.

Ionis Pharmaceuticals reports successful topline results from its Phase 3 OASIS-HAE study, showing donidalorsen significantly reduced the rate of hereditary angioedema attacks.